Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co.

Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., executed multiple sales of common stock on February 20, 2025.

Summary

• Lilly Endowment Inc. sold shares of Eli Lilly & Co. common stock on February 20, 2025.
• The sales were executed in multiple transactions at varying prices.
• A total of 8,937 shares were sold at a weighted average price of $877.436.
• An additional 3,127 shares were sold at a weighted average price of $878.302.
• Further sales included 2,421 shares at a weighted average price of $879.483.
• Finally, 200 shares were sold at a weighted average price of $880.143.
• Following these transactions, Lilly Endowment Inc. still beneficially owns 96,621,862 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale. It doesn't convey any explicit positive or negative sentiment about the company's performance or future prospects.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders and major shareholders. This sale by Lilly Endowment Inc. is a standard disclosure and doesn't necessarily indicate a change in the company's prospects.

Stakeholder Impact

• The sale of shares by a major shareholder like Lilly Endowment Inc. could have a minor impact on investor sentiment, but the overall effect is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, Share Sale, Form 4, Beneficial Ownership, LLY